Viridian Therapeutics, Inc.\DE (VRDN) Share-based Compensation (2014 - 2026)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly Share-based Compensation of $13.4 million for Q1 2026, up 31.02% year-over-year from $10.2 million in Q1 2025, and up 1936.76% quarter-over-quarter from -$729000.0 in Q4 2025.
Viridian Therapeutics, Inc.\DE (VRDN) Share-based Compensation (2014 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Share-based Compensation history runs 13 years deep, the most recent figure standing at $13.4 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 31.02% year-over-year to $13.4 million; the TTM figure through Mar 2026 stood at $3.2 million (up 228.44% YoY), while the FY2023 annual figure was $67.2 million, changed N/A from the prior year.
- Share-based Compensation for Q1 2026 stood at $13.4 million, up from -$729000.0 in the prior quarter.
- The five-year high for Share-based Compensation was $61.5 million in Q4 2023, with the low at -$33.2 million in Q4 2024.
- The 5-year median for Share-based Compensation is $10.2 million (2025), against an average of $4.7 million.
- The sharpest annual moves came in 2023 and 2025: Share-based Compensation soared 524.37% in 2023, then plunged 333.2% in 2025.
- Viridian Therapeutics, Inc.\DE's Share-based Compensation stood at -$14.5 million in 2022, then jumped by 524.37% to $61.5 million in 2023, then slumped by 153.96% to -$33.2 million in 2024, then jumped by 97.8% to -$729000.0 in 2025, then surged by 1936.76% to $13.4 million in 2026.
- Business Quant data shows VRDN's Share-based Compensation at $13.4 million in Q1 2026, -$729000.0 in Q4 2025, and -$20.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Viridian Therapeutics, Inc.\DE | 2.50 Bn | 2.50 Bn | - | 16.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.98 Mn |
| Jun 30, 2026 | 16.98 Mn |
| Mar 31, 2026 | 13.39 Mn |
| Mar 31, 2026 | 13.39 Mn |
| Dec 31, 2025 | -729,000.00 |
| Dec 31, 2025 | -729,000.00 |
| Sep 30, 2025 | -20.34 Mn |
| Sep 30, 2025 | -20.34 Mn |
| Jun 30, 2025 | 10.84 Mn |
| Jun 30, 2025 | 10.84 Mn |
| Mar 31, 2025 | 10.22 Mn |
| Mar 31, 2025 | 10.22 Mn |
| Dec 31, 2024 | -33.18 Mn |
| Dec 31, 2024 | -33.18 Mn |
| Sep 30, 2024 | 8.72 Mn |
| Sep 30, 2024 | 8.72 Mn |
| Jun 30, 2024 | 11.77 Mn |
| Jun 30, 2024 | 11.77 Mn |
| Mar 31, 2024 | 12.69 Mn |
| Mar 31, 2024 | 12.69 Mn |